Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1

Conditions

Uterine Cervical Neoplasms 9Squamous Cell Carcinoma of Head and Neck 9Lung Neoplasms 8Carcinoma, Non-Small-Cell Lung 8Oropharyngeal Neoplasms 6Small Cell Lung Carcinoma 4Nasopharyngeal Carcinoma 4Mesothelioma, Malignant 4Urinary Bladder Neoplasms 3Mouth Neoplasms 3Lymphoid Interstitial Pneumonia 3Laryngeal Neoplasms 3Carcinoma 3Adenocarcinoma of Lung 3Vaginal Neoplasms 2Triple Negative Breast Neoplasms 2Tongue Neoplasms 2Stomach Neoplasms 2Ovarian Neoplasms 2Hypopharyngeal Neoplasms 2Ganglioneuroblastoma 2Carcinoma, Transitional Cell 2Brenner Tumor 2Urethral Neoplasms 1Ureteral Neoplasms 1Stage II Nasopharyngeal Keratinizing Squamous Cell Carcinoma AJCC v7 1Solitary Fibrous Tumor, Pleural 1Sinonasal Squamous Cell Carcinoma 1Salivary Gland Neoplasms 1Resectable Intrahepatic Cholangiocarcinoma 1

Interventions

berzosertib 1Platinum 1Gemcitabine 1Cisplatin 11,2-diaminocyclohexaneplatinum II citrate 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
NIH × Metastatic Bladder Urothelial Carcinoma × Platinum × Clear all
NCT02567409 2025-03-03

Cisplatin and Gemcitabine Hydrochloride With or Without Berzosertib in Treating Patients With Metastatic Urothelial Cancer

National Cancer Institute (NCI)

Phase 2 Completed
87 enrolled 13 charts
Genitourinary

Metastatic Bladder Urothelial Carcinoma

Data powered by HemOnc (CC BY 4.0) Colophon âš¡